• linkedin
  • Increase Font
  • Sharebar

    Tie2 activator augments anti-VEGF for DME

    Seattle—Results from TIME-2, a phase IIA study, support further development of combination treatment with subcutaneous injection of the Tie2 activator, AKB-9778 (Aerpio Therapeutics), plus intravitreous (IVT) anti-VEGF injection for diabetic macular edema (DME), as well as the development of non-IVT therapy for the treatment of diabetic retinopathy.

    Speaking at ARVO 2016, Arshad Khanani, MD, noted that multiple therapeutic approaches to regulate Tie2 activity are under development. AKB-9778 is the only Tie2 targeted compound in clinical trials that has completed a phase II randomized, placebo-controlled study in the setting of retinal disease.

    More from ARVO: Mining data for anti-VEGF therapy insights in PCV

    “TIME-2 provides proof of concept for treatment of diabetic eye disease, both DME and diabetic retinopathy, by activation of Tie2 through inhibition of vascular endothelial-protein tyrosine phosphatase (VE-PTP) mediated by AKB-9778,” said Dr. Khanani, who is in private practice, Reno, NV.

    Dr. Khanani explained that Tie2 is a transmembrane receptor expressed on vascular endothelial cells that exists in an activated state in normal healthy vasculature.

    SPONSORED: Join us for dinner and diabetes management tips! Click here if you’re attending ASCRS!

    In diabetic vasculature, Tie2 is deactivated, which leads to vascular destabilization and leakage. AKB-9778 acts by inhibiting VE-PTP, which is the most critical negative downregulator of Tie2.

    The trial


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';